Journals / Kocaeli Tıp Dergisi / 2014 / Cilt: 3 - Sayı: 1

Current evaluation of pharmacotherapy for overactive bladder

Aşırı aktif mesanede farmakoterapiye güncel bakış

Pages
30–38
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These agents which have alternate mechanism of action and avoid the anticholinergic side effects.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Overactive bladder (OAB) is a prevalent condition that has a significant impact on quality of life.
📊
Key Findings & Data:The usual treatment approach is both behavioral and pharmacological.
💡
Conclusion & Impact:These agents which have alternate mechanism of action and avoid the anticholinergic side effects.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Overactive bladder (OAB) is a prevalent condition that has a significant impact on quality of life. The usual treatment approach is both behavioral and pharmacological. The first-line pharmacological treatment commonly utilizes anticholinergic agents, which may be limited by their tolerability, efficacy, and long-term compliance. Developments in elucidating the pathophysiology of OAB and alternative targets for pharmacological therapy have led to newer agents being developed to manage this condition. These agents which have alternate mechanism of action and avoid the anticholinergic side effects.

Özet

Aşırı aktif mesane (AAM) hayat kalitesi üzerine belirgin etkisi olan yaygın bir tıbbi durumdur. Tedavi yaklaşımı davranışsal ve farmakolojiktir. İlk farmakolojik tedavi alternatifi tolerabilitesi, etkinliği ve uzun dönem komplians gibi sınırlayıcı faktörleri olan antikolinerjik ajanlardır. AAM' nin patofizyolojisinin anlaşılması ve farmakolojik tedavideki alternatif ajan arayışı, bu durumun tedavisi için yeni moleküllerin geliştirilmesini sağlamıştır. Bu moleküllerin antikolinerjik ilaçlarla benzer etkileri olup, yan etkilerinden kaçınmaktadırlar.

🔖

Cite This Article

ÇELİK, O., KARADAĞ, M. A., AKAND, M., ÇEÇEN, K., DEMİR, A., KOCAASLAN, R. (2014). Current evaluation of pharmacotherapy for overactive bladder. Kocaeli Tıp Dergisi, Cilt: 3 - Sayı: 1, 30–38. https://ajindex.com/articles/211270

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Wein AJ, Rackley RR. Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J Urol 2006
  2. Lenderking WR, Nackley JF, Anderson RB, et al. A review of the quality of life aspects of urinary urge incontinence. Pharmacoeconomics 1996
  3. Tarcan T. Aşırı aktif mesane sendromu. Turk Clin Surg Med Sci 2005
  4. Schröder A, Abrams P, Andersson K, et al. Chapple CR,Drake MJ, et al. Guidelines on Urinary incontinence. European Associtation of Urology, 2010. 5.Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther 1995
  5. Lai HH, Boone T, Appell RA. Selecting a medical therapy for overactive bladder. Rev Urol 2002
  6. Sellers DJ, McKay N. Developments in the pharmacotherapy of the overactive bladder. Curr Opin Urol 2007
  7. Glickman S, Tsokkos N, Shah PJ. Intravesical atropine and suppression of detrusor hypercontractility in the neuropathic bladder. A preliminary study. Paraplegia 1995
  8. Thüroff JW, Chartier-Kastler KE, Corcus J, et al. Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 1998
  9. Appell RA. Pharmacotherapy for overactive bladder. Drugs 2006
  10. Moore KH. Step-by-step guide to treatment of overactive bladder (OAB)/Detrusor overactivity. In. Urogynecology: Evidence-Based clinical practice. Ed. Springer-Verlag London Ltd. 2006
  11. Diokno A, Ingber M. Oxybutynin in detrusor overactivity. Urol Clin N Am 2006
  12. Andersson KE, Chapple CR. Oxybutynin and the overactive bladder. World J Urol 2001
  13. Gupta SK, Sathyan G. Pharmacokinetics of an oral once a day controlled release oxybutynin formulation compared with immediate release oxybutynin. J Clin Pharmacol 1999
  14. Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled release oxybutynin in urinary incontinence. The ditropan XL study group. Obstet Gynecol 2000
  15. Sand PK. The evolution of transdermal therapy for overactive bladder. Curr Urol Rep 2009
  16. Hussain RM, Hartigan-Go K, Thomas SH, et al. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 1996
  17. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU 2007
  18. Appell RA